Compare IPCA Labs with AANJANEYA LIFECARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs DR. DATSONS LABS - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS DR. DATSONS LABS IPCA LABS/
DR. DATSONS LABS
 
P/E (TTM) x 24.2 -10.9 - View Chart
P/BV x 4.6 0.2 2,851.7% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 IPCA LABS   DR. DATSONS LABS
EQUITY SHARE DATA
    IPCA LABS
Mar-19
DR. DATSONS LABS
Mar-14
IPCA LABS/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs1,042126 829.6%   
Low Rs59031 1,909.7%   
Sales per share (Unadj.) Rs298.6133.0 224.5%  
Earnings per share (Unadj.) Rs35.00.2 23,085.2%  
Cash flow per share (Unadj.) Rs49.46.6 748.2%  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs247.1128.8 191.9%  
Shares outstanding (eoy) m126.3531.66 399.1%   
Bonus/Rights/Conversions ESOSFCCB-  
Price / Sales ratio x2.70.6 464.4%   
Avg P/E ratio x23.3516.1 4.5%  
P/CF ratio (eoy) x16.511.8 139.4%  
Price / Book Value ratio x3.30.6 543.5%  
Dividend payout %8.60-   
Avg Mkt Cap Rs m103,1082,477 4,161.9%   
No. of employees `00013.4NA-   
Total wages/salary Rs m7,87456 14,060.7%   
Avg. sales/employee Rs Th2,807.0NM-  
Avg. wages/employee Rs Th585.8NM-  
Avg. net profit/employee Rs Th329.0NM-  
INCOME DATA
Net Sales Rs m37,7324,211 896.1%  
Other income Rs m57779 732.9%   
Total revenues Rs m38,3094,289 893.1%   
Gross profit Rs m6,901569 1,213.6%  
Depreciation Rs m1,824204 892.5%   
Interest Rs m189430 43.9%   
Profit before tax Rs m5,46513 43,028.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,0426 17,088.5%   
Profit after tax Rs m4,4225 92,129.2%  
Gross profit margin %18.313.5 135.4%  
Effective tax rate %19.148.0 39.7%   
Net profit margin %11.70.1 10,280.7%  
BALANCE SHEET DATA
Current assets Rs m23,7786,852 347.0%   
Current liabilities Rs m10,9756,711 163.5%   
Net working cap to sales %33.93.3 1,013.2%  
Current ratio x2.21.0 212.2%  
Inventory Days Days104161 64.5%  
Debtors Days Days66318 20.7%  
Net fixed assets Rs m20,3683,673 554.5%   
Share capital Rs m253317 79.8%   
"Free" reserves Rs m30,9713,761 823.5%   
Net worth Rs m31,2244,078 765.8%   
Long term debt Rs m1,4091,671 84.3%   
Total assets Rs m45,50712,633 360.2%  
Interest coverage x30.01.0 2,910.0%   
Debt to equity ratio x00.4 11.0%  
Sales to assets ratio x0.80.3 248.8%   
Return on assets %10.13.4 294.2%  
Return on equity %14.20.1 12,031.1%  
Return on capital %17.37.7 225.8%  
Exports to sales %45.922.9 200.4%   
Imports to sales %16.614.3 116.2%   
Exports (fob) Rs m17,308964 1,795.5%   
Imports (cif) Rs m6,266602 1,041.1%   
Fx inflow Rs m17,308964 1,795.5%   
Fx outflow Rs m6,266607 1,032.2%   
Net fx Rs m11,042357 3,093.9%   
CASH FLOW
From Operations Rs m4,9231,345 366.1%  
From Investments Rs m-1,563-2,256 69.3%  
From Financial Activity Rs m-1,832-1,200 152.7%  
Net Cashflow Rs m1,528-2,111 -72.4%  

Share Holding

Indian Promoters % 45.9 4.5 1,013.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 0.0 -  
FIIs % 25.3 1.4 1,874.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 94.1 18.5%  
Shareholders   36,892 20,807 177.3%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   NATCO PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare IPCA LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 186 Points Higher; Energy and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day on a positive note.

Related Views on News

IPCA LABS at All Time High; BSE HEALTHCARE Index Up 0.5% (Market Updates)

Nov 19, 2019 | Updated on Nov 19, 2019

IPCA LABS share price has hit an all time high at Rs 1,182 (up 1.1%). The BSE HEALTHCARE Index is up by 0.5%. Among the top gainers in the BSE HEALTHCARE Index today are IPCA LABS (up 1.1%) and ABBOTT INDIA (up 0.2%). The top losers include SUN PHARMA ADV. RES. and DISHMAN CARBOGEN AMCIS LTD .

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Nov 19, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS